About the Company
The ImmunityBio COVID-19 vaccine, codenamed hAd5, is a non replicating viral vector COVID-19 vaccine developed by the United States-based pharmaceutical company ImmunityBio.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on ImmunityBio, Inc.
ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results
We recently published 10 Stocks With Whopping 11-97% Upside. ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best-performing ...
ImmunityBio (IBRX) Reports 60% Revenue Growth as ANKTIVA Adoption Accelerates
We recently published 12 Best Healthcare Stocks to Buy Under $30. ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best ...
Why ImmunityBio Inc. (IBRX) Went Up Last Week?
ImmunityBio Inc. (NASDAQ:IBRX) Despite a 6.55 percent drop in Friday’s trading, ImmunityBio managed to finish stronger week-on-week, adding 15.9 percent to its valuation at $3.14 versus the $2. ...
ImmunityBio’s Anktiva Study: A Potential Breakthrough for Long COVID Treatment
Immunitybio Inc (($IBRX)) announced an update on their ongoing clinical study. ImmunityBio Inc. is conducting a study titled ‘Single Arm Study to ...
ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock
Contacts Investors Hemanth Ramaprakash, PhD, MBA ImmunityBio, Inc. +1 858-746-9289 Hemanth.Ramaprakash@ImmunityBio.com Media Sarah Singleton ImmunityBio +1 415-290-8045 Sarah.Singleton@ImmunityBio.com ...
ImmunityBio Reports Third-Quarter 2024 Financial Results
ImmunityBio, Inc. today announced its financial results for the third-quarter ended September 30, 2024. ImmunityBio has secured coverage for over 200 million medical lives through medical ...
ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID
( NASDAQ: IBRX), a leading immunotherapy company, today announced the opening of a new Phase 2 study to assess the BioShield™ platform, anchored by ANKTIVA ® (nogapendekin alfa inbakicept-pmln), in ...
What's Going On With ImmunityBio Stock? - Benzinga
ImmunityBio shares are moving on heavy trading volume Friday. According to data from Benzinga Pro, more than 26.6 million shares have been traded in the session, compared to the stock’s 100-day ...
ImmunityBio: Huge Slump On Small Raise Before Approval Raises Questions
ImmunityBio, Inc. has a May 23 PDUFA for Anktiva with superb data in NMIBC. A recent small $50mn raise from institutional investors broke the stock's back. Most of the huge $700+mn debt is owed to ...
FDA Authorizes Phase 1 Trial of ImmunityBio’s Novel COVID-19 ... - Nasdaq
ImmunityBio, Inc., a privately-held immunotherapy company, today announced it has received authorization from the U.S. Food and Drug Administration to begin a Phase I clinical trial of hAd5-COVID ...
ImmunityBio: Amidst Difficulty Is Your Opportunity
In all, I issued a highly speculative buy recommendation on ImmunityBio, Inc. with a 4.2/5 stars rating. As a "rollercoaster" stock, ImmunityBio is definitely not for the faint of heart.
ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the pricing of its previously announced underwritten public offering of an ...
Similar Companies
Loading the latest forecasts...